Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Open-label Pilot Study to Assess the Use of Magic Foot™ in the Improvment of Parameters in Subject With Foot Symptoms (MF)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by Yaffa Golan, Ltd.
Sponsor:
Information provided by (Responsible Party):
Yaffa Golan, Ltd.
ClinicalTrials.gov Identifier:
NCT01784471
First received: January 30, 2013
Last updated: February 3, 2013
Last verified: February 2013

January 30, 2013
February 3, 2013
November 2012
February 2013   (final data collection date for primary outcome measure)
Changes in total peripheral resistance as assessed by impedance cardiography (ICG) from baseline to day 30 [ Time Frame: From baseline to day 30. ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01784471 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Open-label Pilot Study to Assess the Use of Magic Foot™ in the Improvment of Parameters in Subject With Foot Symptoms
A Pilot Study to Assess the Use of the Magic Foot in the Improvement of Subjective and Objective Parameters in Subjects With Foot Symptoms as a Result of Diabetes or Peripheral Vascular Disease.

This is a single-arm, single-center, open-label, pilot study . 30 subjects with foot symptoms attributable to diabetes or peripheral vascular disease will be screened . Subjects meeting inclusion criteria will sign informed consent and enrolled. All 30 subjects will be treated with the Magic Foot™.

If there is any significant improvement in ICG or foot symptoms as obtained from self evaluation questionnaire, a further 30 subjects will be enrolled.

This is a single-arm, single-center, open-label, pilot study . 30 subjects with foot symptoms attributable to diabetes or peripheral vascular disease will be screened and enrolled. Subjects meeting inclusion criteria will sign informed consent. They will undergo a full examination including blood pressure measurement, heart rate and ECG.

A self evaluation questionnaire relating to foot and sleep disorder symptoms will be completed.

A baseline screening ICG will be performed to measure total peripheral resistance CO (Cardiac Output) and SV (Stroke Volume).

ABI will be performed. The investigational product will be used for 30 minutes and ICG will be repeated.

Each subject will be provided with a size appropriate pair of Magic Foot™ to use at home.

Magic Foot™ will be used for thirty minutes daily for 30 days. This will be done at rest in the evening prior to bedtime. A diary to report compliance will be provided to the subjects. The subject will provide the completed diary to the site staff at day 14 and day 30. Subjects will be reassessed at Day 14. Self evaluation questionnaire will be completed. Subjects will continue with daily use of Magic Foot™. Subject will be reassessed at day 30. ICG, ABI (Ankle Bracial Index) and a final self assessment questionnaire will be repeated at day 30.

At the end of the study the Magic Foot™ will remain with the subjects. In consultation with the treating physician a decision will be made whether to continue with treatment or not.

Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
  • Diabetes
  • Peripheral Vascular Disease
Device: Magic Foot™
Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
Other Name: Magic Foot™
Experimental: Magic foot shoe
Magic Foot™ will be dispensed to all subjects. Shoes will be activated at the clinic for 30 minutes. Subjects will self-use and activate the shoes at home daily for 30 days.
Intervention: Device: Magic Foot™
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
June 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject over the age of 18 with Type 1 / Type 2 diabetes or with PVD (Peripheral vascular disease) or ABI < 0.9 with foot symptoms.
  2. Subject able and willing to comply with the requirements of the protocol.
  3. Subject able to understand and sign written informed consent to participate in the study.

One or more of the following foot symptoms:

  • Pain at rest
  • Pain on activity
  • Nocturnal feet pain
  • Burning sensations
  • Loss of sensation
  • Cold feet
  • Recurrent ulcers , wounds , injuries - longtime to heal

Exclusion Criteria:

  1. Active foot infection
  2. Open ulcer in shoe area
  3. Subjects with unstable or lifethreatening conditions
  4. History of malignancy
  5. Active Charcot arthropathy
  6. Impaired cognitive function -unable to sign informed consent
  7. History of drug or alcohol abuse
  8. Subject currently enrolled or has not yet completed other investigational device or drug study or subject is receiving other investigational agents.
  9. Other conditions based on Principle Investigators judgement
Both
18 Years and older
Yes
Israel
 
NCT01784471
MF-1
No
Yaffa Golan, Ltd.
Yaffa Golan, Ltd.
Not Provided
Principal Investigator: Eliezer Klainman, M.D. Gefen Cardiac Health
Yaffa Golan, Ltd.
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP